Biotech company Metsera, which develops weight-loss drugs and is backed by ARCH Venture Partners, said on Monday that it is ...

Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion.

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

At the beginning of January, Metsera reported preliminary Phase 2a data showing the drug led to dose-dependent weight loss. At the high dose, the average placebo-adjusted weight loss from the ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

The GLP-1 IPO arena has been heating up for the past two years and Metsera’s ask is one the largest in recent history.

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

BofA Securities, Goldman Sachs & Co. LLC, Evercore ISI, Guggenheim Securities and Cantor acted as joint bookrunners for the offering.

Weight-loss drug developer Metsera is targeting an up to $1.78 billion valuation in its initial public offering, the ARCH Venture Partners-backed biotech company said on Monday. New York City-based ...

Metsera seeks to raise up to $292.2 million in US IPO Venture capital firm ARCH Ventures founded Metsera in 2022 Jan 27 (Reuters) - Metsera, which is developing weight-loss drugs, said on Monday ...

By Prakhar Srivastava and Pritam Biswas (Reuters) -Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S. IPO, aiming to ...